Join our Human Tissue Therapy Program. Join Now

Human Tissue Therapy MSK

About Human Tissue Therapy Musculoskeletal (MSK)

Human Tissue Therapy Musculoskeletal (MSK) products utilize human tissue allografts (TAs) derived from living, healthy donors. Once recovered, the TA is filtered through a low-protein binding filter and terminally sterilized with gamma irradiation to ensure recipient safety.

The scientific literature describes tissue allografts as a unique source of anti-inflammatory and anti-microbial proteins. It contains known anti-inflammatory factors such as IL-1 inhibitors α & β and TIMPs. Additionally, tissue allografts are known to contain important growth factors.

About tissue allograft

A tissue allograft is an acellular product and does not contain living, viable cells. Placental tissue derived human tissues are classified under FDA 21 CFR 1271 and PHSA Section 361 as a minimally manipulated allograft intended for homologous use.

The tissue allograft is stored at ambient temperature and is a ready-to-use solution that can be poured directly onto the site of treatment. This human tissue is sourced from tissue providers that are accredited by the American Association of Tissue Banks (AATB) and registered with the Food and Drug Administration (FDA) as a processor of human tissue products.

Tissue Allograft characteristics as described in scientific literature:

Regulation of Inflammation

Tissue allografts are thought to regulate inflammation in the body and to help reconstruct new, healthy tissue.

Human Tissue Therapy

Growth factors are naturally occurring in tissue allografts. Growth factors are responsible for the recruitment of the body’s healing components to promote the tissue repair and reconstruction process.


Tissue allografts are naturally occurring, they do not contain steroids or other pharmaceuticals. Because of the nature of the human tissue the potential for long-term negative health implications is limited.


Tissue allografts are thought to express immune-privileged antigens, which may reduce the risk of graft intolerance. We believe there is very little risk of foreign body reaction.